Advertisement


Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

2016 Pan Pacific Lymphoma Conference

Advertisement

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.



Related Videos

Lymphoma

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.

Lymphoma

Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.

Lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.

Lymphoma

John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?

John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the right patients for these procedures.

Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.

Advertisement

Advertisement




Advertisement